“In our most productive case, we have a smart chance, more than 60%, but we’ll know if the product will work until the end of October,” Bourla said in a recent interview. “That doesn’t mean it paints, it means we’ll know if it works. “
In that regard, Siegel said Bourla told the Food and Drug Administration that another 44,000 people would take a component in a vaccination check: 22,000 will get the vaccine and 22,000 would not.
He told Hemmer that in the early parts of the clinical trial, the vaccine looked promising and produced a “strong immune reaction in patients,” but critics said it would be 50% effective if approved.
“Let me tell you something. With the flu, we have a virus that adapts all the time. But with SARS-COVID-2, it turns out to be pretty consistent,” he says.
“If we don’t shoot a moving target here, there is a smart chance that this vaccine will be much more effective. “
CLICK HERE TO SEE THE FOX NEWS APP
He highlighted how the United States eliminated polio, a vaccine that evolved in the 20th century, as well as smallpox globally, two viruses that were more immutable than otherwise.
“If we get an effective vaccine here, we can actually stop the wave of COVID,” Siegel said. “I like the amount of vaccines that are tested and I like what I hear. I think it’s a very promising situation. “